+3) y post-diagnosis, showed wide variation in spirometric volumes, flows and gas transfer measurements (See table). 1 patient had obstructive, 2 restrictive, 3 mixed patterns, 1 isolated reduction in gas transfer and 2 were normal.

18/21 MSLCH had smoked; mean 12 pack-y. 10 continued smoking after diagnosis. Initial lung function (n=14) at mean 2 (0–12) y post-diagnosis showed slightly less impairment than PLCH but again wide variation.

In PLCH (n=7) at mean follow up of 7 (2–10) y, mean changes in lung function were minor but there was variation; 2 patients deteriorated significantly. 4/9 patients received treatment. To date, 1 has died, 5 are in remission and 3 have active disease.

In MSLCH (n=12) at mean follow up of 7 (1–16) y, mean changes in lung function were minor apart from 2 patients who showed major reductions. 17/21 patients received treatment. To date 3 have died, 12 are in remission and 6 have active disease.

Pulmonary involvement in LCH and impairment of lung function are common in both single and multisystem disease. Changes in lung function over time are very variable with some patients showing marked deterioration and others minor improvement. Lung function determination is important in monitoring all LCH patients with lung involvement.

Abstract P114 Table 1 Pulmonary function values for PLCH and MSLCH

		PLCH	MSLCH
Initial PFT	FEV1	72 (34–113)	81 (66–105)
Mean (range)	VC	78 (53–114)	86 (66–104)
% predicted	TLCO	62 (19–103)	69 (36–108)
At follow up	FEV1	69 (30–103)	76 (49–101)
Mean (range)	VC	82 (51–109)	87 (70–97)
% predicted	TLCO	59 (22–106)	73 (34–105)
Change	FEV1	–5 (–17±8)	–8 (–39±12)
Mean (range)	VC	2 (14±4)	–2 (19±14)
% change	TLCO	–9 (–25±0)	1 (–2±45)

P115 INDUCTION IMMUNOSUPPRESSION (IS) WITH ANTITHYMOCYTE GLOBULIN (ATG) FOLLOWED BY MYCOPHENOLIC ACID (MPA) SIGNIFICANTLY REDUCES RISK OF ACUTE CELLULAR REJECTION (ACR) BUT MAY INCREASE THE RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) POST LUNG TRANSPLANTATION (LTX)

doi:10.1136/thoraxjnl-2012-202678.398

M Al-Aloul, B Al-Skeikley, J Salaie, S Koduri, C Leonard. *Cardiopulmonary Transplant Unit, Wytheshawe Hospital, Manchester, United Kingdom*

Introduction The ideal IS post LTx is unknown and the balance between graft protection against alloimmune injury vs the risks of infection and malignancy is a delicate one. Our unit adopted induction immunosuppression with ATG followed by cyclosporin (CyA), MPA and prednisolone maintenance in 2000 with good outcomes. However, a high burden of leucopenia and concern over increasing numbers of PTLD lead to protocol change in August 2010 where *de novo* azathioprine (AZA) replaced MPA. We now compare short term outcomes of the two strategies.

Methods Two cohorts were compared: cohort 1 (January 2000–July 2010) vs cohort 2 (August 2010–July 2012). ATG 2mg/kg was administered on 3 consecutive post operative days. CyA dosing was guided by trough (C0) and peak (C2) levels. Patients were established on MPA 2–3mg daily in divided doses in the first year and AZA titrated to a maximum of 2mg/kg daily as tolerated. We documented the incidence of biopsy proven PTLD and ACR grade ≥A2,

correcting for confounders. T-tests, Chi squared, multivariate regression and Kaplan Meier statistics were applied.

Results 181 vs 52 underwent LTx in the 2 study periods. There were no differences in age (mean 48yrs [11] vs 49 [13]; gender (M:F 110:71 vs 31:21), type of surgery (Double:Single lung 110:71 vs 34:18). Donor age, cause of death and ischaemia time were similar in the 2 cohorts. 169/181 and 3/52 received MPA vs 12/181 and 49/52 had AZA respectively. CyA dosing and serum levels did not differ between the 2 cohorts. 29 (16%) and 18 (34%) experienced ACR respectively (P<0.05). 15 patients in cohort 1 developed PTLD (mean age 54 [range 26–63], mean interval from surgery at diagnosis 286 days [73–790], 11/15 developed PTLD in the first post-op year) vs none in cohort 2. Donor:recipient EBV serostatus was similar in the 2 cohorts. Bacterial and fungal infections were documented in 94 vs 25 and 41 vs 7 respectively. Pseudomonas was isolated from a similar percentage in the 2 groups (59 vs 17). CMV viraemia necessitating pre-emptive therapy with valganciclovir was observed in 56 (32%) vs 10 (19%), P<0.05 despite similar distribution of donor:recipient CMV serostatus.

Conclusion ATG/MPA combination may better protect lung allografts against acute rejection but at the expense of a higher burden of lymphoma and infection. Valganciclovir enhances MPA bio-availability and the high prevalence of CMV activation after ATG/MPA may be a contributor to our observations. Longer term data, including other malignancies, would further inform this debate.

P116 OUTCOMES OF DCD LUNG OFFERS: A SINGLE CENTRE EXPERIENCE IN THE UK

doi:10.1136/thoraxjnl-2012-202678.399

C Newark, J Parmar, J Dunning, S Tsui. *Papworth Hospital, Cambridge, United Kingdom*

Introduction Lung transplantation is the treatment of choice for a variety of end stage lung diseases. It offers prognostic benefit and an improvement in quality of life for carefully selected patients. There sadly remains a critical shortage of lung donors. One way to increase the donor pool, and potentially the number of lung transplants, is to utilise organs which are Donated following Circulatory Death (DCD). Here we review our experience with DCD offers received during a two-and-a-half year period.

Methods This is a retrospective study using data collected prospectively from all lung offers received between 01/2009 – 09/2011. We look at the proportion of DCD lung offers and track the fate of each of these down to transplantation. We look at the documented reasons for declining all DCD lung offers, the rate of DCD lung transplantation and the survival rate in this cohort.

Results Overall, 80 lung transplants were performed during the study period. 7 were performed using DCDs, therefore, 9% of lung transplants are from DCD donors. Survival rate at 1 year post-DCD lung transplantation is approximately 80%.

233(86%) of DCD lung offers were initially declined. Numerous reasons were documented; the most common reason given (122 donors) was due to evidence of infection. In 37 cases, the donor was unlikely to meet extubation criteria. Interestingly, 42 donors were declined as a result of having no suitable recipient on the transplant waiting list alone.

A large proportion of offers were initially accepted but not used. In 5 cases consent for transplantation was withdrawn from family, 7 cases were declined due to time/logistical factors and 10 donors were declined on inspection from the retrieval team.

Conclusion Despite offering good short term outcomes, a large number of DCD lungs are declined for a variety reasons. Donors declined due to having no suitable recipient could be reduced by increasing the number of patients on the waiting list. Increased public awareness and better communication leading up to donation